LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 30.090
- +1.560+5.47%
Close Feb 28 16:00 ET
- 30.110
- +0.020+0.07%
Post 19:58 ET
4.68BMarket Cap-300.90P/E (TTM)
30.370High28.170Low2.42MVolume28.300Open28.530Pre Close71.47MTurnover1.67%Turnover Ratio334.33P/E (Static)155.67MShares36.84052wk High24.38P/B4.36BFloat Cap12.93052wk Low--Dividend TTM144.91MShs Float149414.006Historical High--Div YieldTTM7.71%Amplitude0.956Historical Low29.530Avg Price1Lot Size
About TG Therapeutics Company
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Company Profile
SymbolTGTX
Company NameTG Therapeutics
Listing DateOct 7, 2005
Founded1993
CEOMr. Michael S. Weiss
MarketNASDAQ
Employees264
Fiscal Year Ends12-31
Address3020 Carrington Mill Boulevard,Suite 475
CityMorrisville
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27560
Phone1-212-554-4484
Company Executives
- Name
- Position
- Salary
- Michael S. Weiss
- Chairman of the Board, Chief Executive Officer and President
- 15.84M
- Sean A. Power
- Chief Financial Officer, Treasurer and Corporate Secretary
- 1.87M
- Laurence N. Charney
- Lead Independent Director
- 304.70K
- Sagar Lonial, M.D.
- Independent Director
- 259.70K
- Kenneth Hoberman
- Independent Director
- 264.70K
- Daniel Hume
- Independent Director
- 262.20K
- Dr. Yann Echelard
- Independent Director
- 262.20K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025